Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPBPE001.1
- Development stage
- Preclinical
- Lead developer
- Ambiotech
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
HPBPE001.1 is an exosome-based therapy currently in preclinical development by AM Biotech. It is being investigated for the treatment of premature ovarian failure, menopausal symptoms, and intimate area care. The drug is developed using AM Biotech's proprietary Biochemical Pulse Exosome Drug Development Platform, which focuses on creating therapeutic exosomes with specific bioactive cargo. As an exosome therapy, HPBPE001.1 likely functions by delivering proteins, lipids, or nucleic acids to target cells to modulate physiological pathways associated with ovarian function and hormonal balance, although its specific molecular targets have not been publicly disclosed.
Beyond the preview
Go deeper on HPBPE001.1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPBPE001.1.